Molecular Formula | C20H22NNaO4 |
Molar Mass | 363.38275 |
Melting Point | 240.0~244.0 °C |
Storage Condition | 2-8℃ |
In vitro study | Efaproxiral, a synthetic allosteric modulator of the binding affinity of hemoglobinoxygen, has been shown to reversibly bind to hemoglobin, stabilizing the conformation of the deoxyhemoglobin tetramer to reduce its affinity for oxygen. |
In vivo study | In mice breathing air and oxygen, efaprox Iral and oxygen respiration reduced the radiobiological hypoxia fraction of EMT6 tumors from 24% to 9%, increasing the tumor response to radiation. Efaproxir and oxygen increased growth delay to 5.7 days, which was 2.4 days (71%) higher than Carboplatin alone and 2.1 days (57%) higher than Carboplatin and oxygen. Thus, efaproxir and oxygen respiration increased the tumor suppressor effect of 100 mg/kg and 150 mg/kg carboplatin, but did not increase the toxicity of 100 mg/kg carboplatin in mice breathing air. In C3H mice with RIF-1 tumors, efaproxir significantly increased tumor oxygenation, from 8.4 to 43.4 Hg within 5 days, with the maximum increase occurring at 22-31 minutes post-treatment. In C3H mice with RIF-1 tumors, efaprox IR plus oxygen plus radiation resulted in tumor growth inhibition that was significantly different from radiation plus oxygen from Day 3 to day 5. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.752 ml | 13.76 ml | 27.519 ml |
5 mM | 0.55 ml | 2.752 ml | 5.504 ml |
10 mM | 0.275 ml | 1.376 ml | 2.752 ml |
5 mM | 0.055 ml | 0.275 ml | 0.55 ml |